Five Prime Therapeutics — Technical Presentation (November 2020)
14 slides from Five Prime Therapeutics's technical presentation, Nov 10, 2020
Slide 1: Bemarituzumab Targeted Therapy for FGFR2b+ Tumors
Exhibit 99.2 Bemarituzumab Targeted Therapy for FGFR2b+ Tumors November 10, 2020 © 2020 Five Prime Therapeutics, Inc.Exhibit 99.2 Bemarituzumab Targeted Therapy for FGFR2b+ Tumors November 10, 2020 © 2020 Five Prime Therapeutics, Inc.
Slide 2: Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate and similar expressions (as well as other words or expressions referencing future
Slide 3: Executive Summary: Bemarituzumab Value Proposition
Executive Summary: Bemarituzumab Value Proposition targeting FGFR2b+ advanced gastric and First-in-class gastroesophageal junction (GC/GEJ) cancers antibody FIGHT Phase 2 Results PFS, OS, ORR PFS HR=0.68 (95% CI: 0.44-1.04; p=0.073) statistically OS HR=0.58 (95% CI: 0.35-0.95; p=0.027) 1 significant
Slide 4: Gastric Cancer Has Global Impact and a Poor Prognosis
Gastric Cancer Has Global Impact and a Poor Prognosis 1 Gastric Cancer Incidence 1 million+ cases globally 1M+ each year rd 3 most common cause 1 of cancer death globally 3rd After lung and breast cancer 5th Most 1 Common Cancer After lung, breast, prostate 5th and colon cancer Unmet Medical Need 2
Slide 5: Bemarituzumab (Bema) MoA
Bemarituzumab (Bema) MoA © © 2 202 020 0 F Fiiv ve e P Pr riim me e T The her ra ape peu ut tiic cs s, , I In nc c. . 5Bemarituzumab (Bema) MoA © © 2 202 020 0 F Fiiv ve e P Pr riim me e T The her ra ape peu ut tiic cs s, , I In nc c. . 5
Slide 6: Overview of Bemarituzumab Clinical Development
Overview of Bemarituzumab Clinical Development Study Objective(s) Results FGFR2b Selected Number of patients Phase 1 Monotherapy Tolerability, safety and preliminary efficacy of monotherapy ORR 18% in late-line FGFR2b+ Gastric / Mixed 1 (n=79) in late-line patients GEJ Phase 1 Monotherapy Tolerabili
Slide 7: FIGHT: Phase 2 Randomized Trial in Frontline FGFR2b+, non HER2+ Gastric/GEJ Cancers
FIGHT: Phase 2 Randomized Trial in Frontline FGFR2b+, non HER2+ Gastric/GEJ Cancers fiveprime.com | NASDAQ: FPRX © © 2 202 020 0 F Fiiv ve e P Pr riim me e T The her ra ape peu ut tiic cs s, , I In nc c. . 7FIGHT: Phase 2 Randomized Trial in Frontline FGFR2b+, non HER2+ Gastric/GEJ Cancers fiveprime
Slide 8: FIGHT Trial Design
FIGHT Trial Design Patients Selected for FGFR2b+ Tumors (~30% of all non-HER2+ Gastric/GEJ Cancer) Key Eligibility Criteria • No prior therapy for unresectable Bema + mFOLFOX6 locally advanced or metastatic Primary endpoint (n = 77) gastric or GEJ adenocarcinoma Progression-Free • RECIST v1.1 evalua
Slide 9: Primary and Secondary Efficacy Endpoints with Statistical Significance
Favor Placebo 1 Primary and Secondary Efficacy Endpoints with Statistical Significance Hazard Ratio MEDIAN PFS/OS (MON) HR (95% CI) ENDPOINT RESPONSE RATE DIFFERENCE IN ORR (95% CI) 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2 Bema: 9.5 0.68 (0.44, 1.04) PFS Placebo: 7.4 p=0.073 Bema: NR 0.58 (0.35, 0.95) OS P
Slide 10: Results from Front-Line Gastric Cancer Trials
Results from Front-Line Gastric Cancer Trials ToGA Trial CheckMate-649 Trial FIGHT Trial (nivolumab; CPS ≥5/HER2-) (bema; FGFR2b+/non HER2+) (trastuzumab; HER2+) Global including Global not including Global including Endpoint South Korea & Japan South Korea or Japan South Korea & Japan HR = 0.71 HR
Slide 11: Summary of Treatment-Emergent Adverse Events (TEAEs)
Summary of Treatment-Emergent Adverse Events (TEAEs) Bema (N = 76) Placebo (N = 77) Total (N = 153) All TEAE 76 (100.0%) 76 (98.7%) 152 (99.3%) Grade ≥ 3 63 (82.9%) 57 (74.0%) 120 (78.4%) Leading to death (Grade 5) 5 (6.6%) 4 (5.2%) 9 (5.9%) SAE 24 (31.6%) 28 (36.4%) 52 (34.0%) SAE related to any st
Slide 12: Summary of FIGHT Phase 2 Top-Line Results
Summary of FIGHT Phase 2 Top-Line Results Primary endpoint Secondary efficacy endpoints st 1 secondary endpoint OS: Bema is superior to Primary endpoint PFS: Bema is superior to placebo placebo 1 • HR = 0.68 (95% CI: 0.44, 1.04; p=0.073 ) 1 • HR = 0.58 (95% CI: 0.35, 0.95; p=0.027 ) • Median PFS (mo
Slide 13: Potential Development Opportunity in Other FGFR2b+ Tumors
Potential Development Opportunity in Other FGFR2b+ Tumors FGFR2b+ Rate Estimated Global 1 Tumor Type Global Prevalence (2+ / 3+ IHC Cutoff) FGFR2b+ Population (Study source) 31% NSCLC-Squamous 543,141 ~150,000 (Ventana data, n=100) 13% TNBC 825,012 ~100,000 (Five Prime data, n=97) 40% Ovarian cancer
Slide 14: Bemarituzumab Targeted Therapy for FGFR2b+ Tumors
Bemarituzumab Targeted Therapy for FGFR2b+ Tumors November 10, 2020 © 2020 Five Prime Therapeutics, Inc.Bemarituzumab Targeted Therapy for FGFR2b+ Tumors November 10, 2020 © 2020 Five Prime Therapeutics, Inc.
Five Prime Therapeutics — Technical Presentation (November 2020) on 6ix